Aesthetic Medicine
Aesthetic Medicine


3 MIN READ TIME

Sculpting the future

Before
After

When it comes to skin, a common concern of patients aged 39-45 is matching up the way they look with the way they feel. Place the control back into the hands of your patients to manage the effects of skin ageing with Sculptra.

As skin ages, the natural loss of collagen leads to thinner and structurally weakened skin. 1,2 Sculptra activates the body’s natural ability to produce collagen, restoring the skin’s structure and renewing its natural firmness. 3-7

When choosing a treatment, patients find long-lasting results more important than how quickly those results appear. Dr Munir Somji explains why he likes using Sculptra with his patients: “I find Sculptra to be a unique injectable bio-stimulant that can be injected in a multi-layer fashion to yield individualised results for patients of a wide age range.

“I see Sculptra as a tool to address a number of skin concerns such as skin laxity and volume loss, thanks to its collagen-stimulating properties, and it is the perfect ‘base’ treatment for my patients. Sculptra stimulates the development of new collagen – the primary source of improved skin firmness and volume. With accurate patient selection the results of Sculptra are gradual, very natural, and can last up to 24 months or more, and I do find results can last longer.” he says.

MODE OF ACTION AND EFFICACY

Sculptra restores volume by revitalising collage production to improve the skin’s inner structure. 3,4,6

Key benefits:

• Long-lasting – Sculptra renews the skin by restoring volume and smoothing wrinkles up to 25 months after the last treatment. 6,9-11,

• Collagen stimulation – Sculptra restores volume by revitalising collagen production to improve the skin’s inner structure. 3,4,6

• Creating patient delight – 96.6% of patients rated Sculptra good to excellent. 15

NEW SCULPTRA GAIN TRAINING

Become a Sculptra Centre of Excellence Sculptra training as part of the Galderma Aesthetic Injector Network (GAIN) will host face-to-face injection technique coaching plus on-going support covering topics such as how to use the product effectively, advice on specific cases and how to add the treatment to your clinic portfolio. In addition, GAIN will also provide branded materials including point-of-sale promotional tools to help practitioners increase engagement and generate sales which are available to all accounts purchasing from Galderma’s preferred provider, Medfx.

The Sculptra GAIN program is available by invitation only for advanced injectors with successful completion of the training programme. To book your place on a Sculptra course please contact your Galderma key account manager.

Galderma | Empowering Beauty in all forms for 40 years. Sculptra and Galderma are trademarks owned by Galderma S.A.

DOP: UKI-SCU-2100077 DOP October 2021 .

Adverse events should be reported. For the UK, reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. For Ireland, suspected adverse events can be reported via HPRA Pharmacovigilance, www.hpra.ie; Adverse events should also be reported to Galderma (UK)

Ltd. E-mail: Medinfo.uk@galderma.com Tel +44 1 923 208950.

REFERENCES

1. Farage MA etal.AdvWoundCare(NewRochelle)2013;2(1):5–10.

2. Quan T and Fisher GJ. Gerontology 2015;61(5):427–34.

3. Stein P et al. J Dermatol Sci 2015;78(1):26–33.9.

4. Goldberg D et al. Dermatol Surg 2013;39(6):915–22.

5. Vleggaar D et al. J Drugs Dermatol 2014;13 (4 suppl):s29–31.

6. Moyle GJ et al. HIV Med 2004;5(2):82–7.

7. Bohnert K et al. Plast Reconstr Surg 2019;127(4):1684–92.C2.

8. Weinkle S and Lupo M. J Clin Aesthetic Dermatol2010;3(9):30–33

9. Narins RS et al. J Am Acad Dermatol2010;62(3):448–62.

10. Brandt FS et al. Aesthet Surg J2011;31(5):521–8.

11. Nelson L and Stewart KJ. J Plast Reconstr Aesthet Surg 2012;65(4):439–47.

12. Mest DR and Humble G. Dermatol Surg2006;32(11): 1336–45.

13. Chen HH et al. JAMA Facial Plast Surg2015;17(1):39–43.

14. Valantin MA et al. AIDS 2003;17(17):2471–7.

15. Brown SA et al. Plast Reconstr Surg 2011;127(4):1684-1692

For more information visit galdermaaesthetics.com, email digital.uk@galderma.com or call +44 (0) 192 320 8950

This article appears in the November/December 2021 Issue of Aesthetic Medicine

Click here to view the article in the magazine.
To view other articles in this issue Click here.
If you would like to view other issues of Aesthetic Medicine, you can see the full archive here.

COPIED
This article appears in the November/December 2021 Issue of Aesthetic Medicine